VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

ASCO GI 2021 | LY3410738: a first-in-class covalent inhibitor of mutant IDH1 in CCA

Rachna T. Shroff, MD, University of Arizona Cancer Center, Tucson, AZ, discusses an ongoing Phase I study evaluating LY3410738, a first-in-class covalent inhibitor of mutant IDH1 in cholangiocarcinoma (CCA) and other advanced solid tumors. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter